




# PHARMACEUTICAL 2023

GT Biopharma Inc.  
Rank 306 of 446





# PHARMACEUTICAL 2023

GT Biopharma Inc.  
Rank 306 of 446

The relative strengths and weaknesses of GT Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of GT Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -6.5%, being 50% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,562
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,938
Liabilities, Non-Current	64
Other Assets	174
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	373
Other Revenues	0
Property and Equipment	0
Research and Development	8,811
Selling, General and Administrative Expense	12,446

Output Variable	Value in 1000 USD
Assets	16,736
Liabilities	5,002
Expenses	21,257
Revenues	0
Stockholders Equity	11,734
Net Income	-20,884
Comprehensive Net Income	-20,884
Economic Capital Ratio	-6.5%